Pharmaceutical giant Eli Lilly (NYSE: LLY) has been the winner in the massive GLP-1 drug category, the class of medications that have proven extremely effective in lowering blood sugar levels and ...

Eli Lilly has struck a deal to buy genetic-medicine biotechnology company Orna Therapeutics for up to $2.4 billion in cash. Eli Lilly on Monday said Orna, which is dedicated to engineering immune ...

Feb 9 (Reuters) - Eli ‌Lilly will ‌acquire therapy developer ⁠Orna ‌Therapeutics for ‍up to $2.4 billion ‌in cash, the companies said ⁠on Monday.

Eli Lilly is continuing a run of dealmaking to strengthen its genetic medicine offering by penning a pact with gene editing company Seamless Therapeutics. This morning’s deal with Seamless centers on ...

Eli Lilly is expanding its footprint in genetic medicine, announcing Wednesday an agreement with Germany-based startup Seamless Therapeutics to develop treatments for hearing loss. The alliance gives ...

Nvidia Corp. is partnering with Eli Lilly and Co. to open a research lab that will use artificial intelligence to speed up drug discovery. The companies announced the collaboration today. They plan to ...

Warm summer days at camp may feel far off, but they are top of mind for a dozen northeast Indiana youth camps that received welcome news this month. They were among nearly 70 organizations statewide ...

Page Six may be compensated and/or receive an affiliate commission if you click or buy through our links. Featured pricing is subject to change. Say “oui” to effortless beauty. Award-winning celebrity ...

Eli Lilly LLY10.33%increase; green up pointing triangle said its next generation weight-loss drug retatrutide helped people lose up to 28.7% of their body weight after more than a year of treatment, ...

Forbes contributors publish independent expert analyses and insights. Peter Cohan, a Boston-based senior contributor, covers stocks. Eli Lilly achieved a $1 trillion market cap, a healthcare first, ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Merck, which has claimed ...